MedTrace Logo

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

NCT07216859 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2025-11-17

No results posted yet for this study

Summary

The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs).

The main question it aims to answer is to:

1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment.
2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.

Conditions

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Cirrhosis

Interventions

OTHER

AI-Enabled Identification (EchoNet-Liver)

AI-generated notifications to clinicians about possible undiagnosed liver disease (MASLD and/or Cirrhosis) detected from Transthoracic Echocardiogram

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • Kaiser Permanente

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-11-01
Completion
2027-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07216859 on ClinicalTrials.gov